RNA Technologies Expand Tool Kit for Cancer Immunotherapy
Elie Dolgin • October 1, 2019
Multiple companies are pursuing mRNA-based medicines that harness the body's protein-making machinery to transform lab-synthesized nucleotides into cancer-associated antigens, in the case of vaccines, or immune-stimulating molecules, in the case of therapeutics. Several candidates from BioNTech and Moderna have shown promise in early-stage testing.
Continue reading at Cancer Discovery.
With organoids, assembloids and a growing bioengineering toolkit, scientists are pushing the limits of human brain models.
Drug makers are scrambling to navigate an ‘existential threat’ to a once-celebrated technology.